Compare Revvity Inc (RVTY) vs Tidewater Inc (TDW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Revvity Inc vs Tidewater Inc — how do they compare? Revvity Inc trades at $154.18 (market cap $16.98B), while Tidewater Inc trades at $85.42 (market cap $4.21B). The key difference: Revvity Inc is far larger — about 4× Tidewater Inc's market cap, and Revvity Inc pays a 0.18% dividend while Tidewater Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Revvity Inc for 12 Days and Tidewater Inc for 26 Days on average.
| RVTY | TDW | |
|---|---|---|
Market Cap | $16.98B | $4.21B |
Volume | 1,456,900 | 590,005 |
Sector | Health | Energy |
52-Week High | $157.36 | $100.61 |
52-Week Low | $82.26 | $47.29 |
Typical Hold Time | 12 Days | 26 Days |
Enterprise Value | $19.30B | $4.25B |
Dividend Yield | 0.18% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RVTY trades at $152.16, down 0.94% on the day, but maintains a bullish technical trend with strong moving average signals and support near $149. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected soon. Revenue remains stable around $2.9 billion, though net income margins have softened slightly. Recent news highlights product launches and strategic acquisitions, such as the Human Cell Design deal, to bolster its life sciences portfolio.
The outlook is supported by analyst optimism with a 51.72% buy rating and a consensus price target of $132.13, though the current price trades above this target. Key risks include premium valuation metrics, margin pressures, and exposure to macroeconomic headwinds. The stock's proximity to its 52-week high suggests momentum but warrants caution given rich multiples.
Tidewater (TDW) trades at $84.70, up 1.56% today, with a bullish technical signal from moving averages and a consensus analyst price target of $105.50. The company reported strong 2025 results with $1.35B revenue and $334.66M net income, though 2026 shows a decline. Recent news includes the completion of the Wilson Sons Ultratug acquisition and significant institutional buying by BlackRock.
The stock offers upside to the price target but faces risks from earnings volatility, as seen in recent quarterly misses, and exposure to energy market cycles. Investor sentiment is mixed with a majority hold rating from analysts, indicating cautious optimism amid operational execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →About Tidewater Inc
Tidewater is the leading global provider of offshore support vessels (OSVs) to the energy industry. With the world's largest fleet of platform supply vessels (PSVs) and anchor handling tugs (AHTS), it provides critical logistics and marine support for offshore oil, gas, and renewable energy projects. Following a period of massive strategic consolidation, Tidewater is now focused on maximizing day rates and free cash flow in a supply-constrained market, positioning itself as a primary beneficiary of the multi-year offshore upcycle.
Read more on TDW →
